Self-Expanding Valve vs. Balloon-Expandable Valve, Randomized, Head to Head

The “arms race”among transcatheter valves has been vertiginous. By the time we received the mid- or long-term outcomes of studies focused on a given valve, we were already using its next generation in clinical practice.

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

As a result, there is little information addressing which valve is the best.

Nowadays, this “arms race” has reached a plateau. There is a third generation for the two most frequent commercially available valves, including design changes to solve the same problems (access profile, rate of pacemaker implantation, paravalvular leak, proper implantation).

SOLVE-TAVI is a multicenter trial that included 447 patients with severe aortic stenosis undergoing transfemoral transcatheter aortic valve replacement who were randomized to self-expanding valve (Evolut R, Medtronic Inc., Minneapolis, MN, USA) or balloon-expandable valve (Sapien 3, Edwards Lifesciences, Irvine, CA, USA).


Read also: In Search of the Optimal Depth for Self-Expandable Valves.


The primary efficacy endpoint was a composite of all-cause mortality, stroke, moderate or severe paravalvular regurgitation, and permanent pacemaker implantation at 30 days.

The composite endpoint occurred in 28.4% of patients who received Evolut R vs. 26.1% of patients who received Sapien 3 (Pequivalence = 0.04)

The individual components also met the equivalence criteria, with the following rates: all-cause mortality, 3.2% vs. 2.3%; stroke, 0.5% vs. 4.7%; moderate/severe paravalvular regurgitation, 3.4% vs. 1.5%; and permanent pacemaker implantation, 23% vs. 19.2%.

Conclusion

The newer generations of the two most used commercially available valves were equivalent as regards the efficacy and safety endpoints in patients with severe aortic stenosis undergoing transfemoral transcatheter aortic valve replacement.

These findings support the equal use of both valves in most patients, with some specific preferences based on individual valve anatomy.

Original Title: Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial.

Reference: Holger Thiele et al. European Heart Journal (2020) 41, 1890–1899 doi:10.1093/eurheartj/ehaa036.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...